Sandoz Ag

Sandoz Gmbh

Franz Xaver Schwarz

Johannes Raneburger

Irina Kosilek

Stefan Scheler

Andreas Hotter

Arthur Pichler

Thomas Jakob

Heiko Degendorfer

Robert Reichenberger

Hans W Bilke

Otto Daemon

Florian Kern

Szabolcs Szerdi

Johann Bacher

Indranil Nandi

Mintong Guo

Georg Anker

Chad Michael Gassert

Hans Werner Bilke

Stefan Horkovics-Kovats

Markus Wiedmann

The present invention relates to an oral dosage form containing rifaximin in form beta, wherein the oral dosage form provides delayed release of the active pharmaceutical agent. Further, the invention relates to the preparation of an oral dosage form, preferably a tablet.

Oral dosage form comprising rifaximin in form beta

The present invention relates to a pharmaceutical composition containing a stable polymorph of rifaximin and a wicking agent as well as a method of preparing the same.

Storage stable composition comprising rifaximin alpha

The present invention relates to a stable pharmaceutical composition comprising amorphous or crystalline linagliptin or a pharmaceutically acceptable salt of linagliptin, mannitol, copovidone, and magnesium stearate, processes for preparing the stable pharmaceutical composition, and a container comprising the stable pharmaceutical composition.

Stable pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof

The invention relates to a capsule comprising an inlet and an outlet connected by a passage, in which a dissolvable blocking element and a composition to be orally administered are arranged. The blocking element is fluid permeable and, in a non-dissolved condition, is arranged in the passage to block delivery of the composition to an outlet of the passage. The invention further relates to a method for releasable sealing a capsule comprising a composition to be orally administered, comprising the steps of providing the composition chamber in a passage and filling composition into the composition chamber. The passage formed by the capsule is occluded with a blocking element and the blocking element comprises dissolvable material and has a fluid permeable structure.

Capsule with soluble blocking element

The present invention provides a pharmaceutical formulation prepared as dry syrups representing mere powder mixtures of beta-lactam antibiotics as active pharmaceutical ingredients and excipients without applying any other process steps than simple mixing of dry powder, whereby the pharmaceutical formulation combines two essential properties for processability and dosability: good flowability and high stability against segregation.

Powder mixtures for antibiotic dry syrup formulations

A device for oral application of a substance, comprising an inner tube surrounding a first volume an outer tube surrounding a second volume, the second volume comprising a cavity section adjoining an inlet opening of the outer tube being adapted for containing the substance, a separation area arranged in the second volume, the separation area adjoining the cavity section and the first volume, and a selective connecting passage between the cavity section and a pressure compensation space to selectively enable a flow of the substance from the cavity section though the first volume. A kit-of-parts, comprises the inventive device a predefined amount of a substance being contained in a receptacle or the cavity section, and instructions for the use of the substance. Methods for filling the inventive device as well as to a method for oral application using the inventive device are provided.

Device for the oral application of a substance

The present invention relates to an oral solid dosage form, in particular a tablet, comprising sorafenib tosylate polymorphic form III.

Pharmaceutical composition containing crystalline sorafenib tosylate

The invention relates to a device for oral application of a composition. The device comprises recess having an outer rim encompassing the recess. Within the recess, a composition is arranged. The composition comprises a gelling agent and an active agent. A cover member is attached to the rim and completely covers the recess. Thus, the cover member, together with the recess, retains the composition within the recess. The cover member has an outer surface opposed to an inner surface adjoining the recess. In order to allow preparation of the composition by adding water without the risk of losing some of the composition during preparation, the cover member comprises one or more openings for providing fluidic connection between the inner surface and the outer surface. Through this opening, water can enter for preparing the composition meanwhile the cover retains all composition within the recess. The invention further relates to a method for manufacturing the device. The solid composition is introduced into the recess and the cover member is attached to the rim. The method further comprises to provide the cover member with one or more openings. The openings are adapted for providing fluidic connection between the inner surface and the outer surface of the cover member.

Method and device for oral application of a composition

A novel process for preparing stable granulate which comprises amoxicillin trihydrate and a sugar, and to novel stable granulate comprising amoxicillin trihydrate and the sugar as well, for reconstitution with water into fine stable homogeneous aqueous suspension is described. The novel process omits preliminary process step for preparing fine particle size of micronized amoxicillin trihydrate used subsequently in the granulation process known in the art, for example grinding or micronizing of said antibiotic. In a preferred aspect of the invention the novel stable granulate comprises amoxicillin trihydrate and the sugar, preferably sucrose, free of any pharmaceutically acceptable excipient. Novel granulate, which is easily dissolved in water to form smooth aqueous suspension immediately, is used for treating bacterial infections in humans or animals, especially in pediatric patients and in the geriatrics.

Amoxicilline instant granulate

An oral suspension comprising (a) an antibiotic composition which comprises coated micropellets and optionally one or more excipients, (b) additional excipients, and (c) a solvent, wherein said coated micropellets comprise (i) a core comprising at least one antibiotic; (ii) an inner coating comprising at least one cellulose polymer which is not an enteric coating polymer; and (iii) an outer coating comprising at least one enteric coating polymer, wherein said coated micropellets have a mean particle size of about 100 &#x3bc;m to about 650 &#x3bc;m. The oral suspension of the invention is characterized by a lack of bitter taste.

Antibiotic clarithromycin micropellet compositions

Process for drying amoxicillin (compositions), characterised in that a gas, which is inert towards amoxicillin (compositions) and having a relative humidity content which is greater than zero is used for drying.

Process for drying amoxicillin

The present invention relates to a pharmaceutical composition for oral administration suitable for the preparation of a ready-to-use suspension comprising coated particles comprising an active substance having an unpleasant and/or bitter taste, such as clarithromycin, and a suspension base comprising an osmotically active substance capable of providing a high osmolality to the admixture of the suspension base with an aqueous suspending medium in the ready-to-use suspension. Said ready-to-use suspension maintains its palatability over a prolonged period of time by those defined osmotic conditions.

Growing community of inventors

Kundl, Austria

Franz Xaver Schwarz